All News

Found 3,195 articles

• Vincerx Pharma Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022

  12/11/2022

  Vincerx Pharma, Inc. announced a poster presentation of preclinical data of Vincerx’s proprietary payload and linker technology and VIP943, the Company’s internalizing ADC targeting CD123, at the 64th American Society of Hematology Annual Meeting 2022.

• ImmunoGen Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH

  12/10/2022

  ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced initial safety and efficacy findings from dose-escalation and expansion cohorts of the Phase 1b/2 study of pivekimab sunirine in combination with Vidaza® and Venclexta® in patients with relapsed/refractory and frontline acute myeloid leukemia.

• Sutro Biopharma Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022

  12/10/2022

  Sutro Biopharma, Inc. announced that its research collaborators at Fred Hutchinson Cancer Research Center presented data from the Compassionate Use Program on anti-leukemic activity of STRO-002 in pediatric patients with relapsed/refractory CBFA2T3-GLIS2 acute myeloid leukemia, commonly known as RAM phenotype AML, in an oral presentation at the 64th ASH Annual Meeting and Exposition in New Orleans, LA.

• Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment

  12/9/2022

  ​Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using its proprietary Engineered Precision Biologics (EPBs) platform to create antibody drug conjugates (ADCs), today announced preliminary safety and efficacy data from its Phase 2 ACE‑Breast-03 study during a Spotlight Poster Presentation at the 2022 San Antonio Breast Cancer Symposium (SABCS).

• Defence Therapeutics Appoints Kwin Grauer to Its Board of Directors

  12/9/2022

  Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the appointment of Mr. Kwin Grauer to its board of directors, effective immediately.

• 

  Dantari Debuts with $47M to Make Better ADCs

  12/8/2022

  With $47 million in hand, Dantari launched Thursday to advance its Targeted High-capacity Drug Conjugate technology – its take on an antibody-drug conjugate - for solid tumors.

• Capivasertib Plus FASLODEX® (fulvestrant) Reduced the Risk of Disease Progression or Death by 40% Versus FASLODEX in Advanced HR-Positive Breast Cancer

  12/8/2022

  Detailed results from the CAPItello-291 Phase III trial showed AstraZeneca’s capivasertib in combination with FASLODEX® demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo plus FASLODEX in patients with hormone receptor -positive, human epidermal growth factor receptor 2 -low or negative, locally advanced or metastatic breast cancer, following recurrence or progression on, or after, endocrine therapy.

• Phanes Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate PT199 in combination with Tislelizumab

  12/8/2022

  Phanes Therapeutics, Inc. (Phanes) today announced a clinical supply agreement with BeiGene, Ltd. (NASDAQ: BGNE) to evaluate the safety and efficacy of Phanes' PT199, a differentiated anti-CD73 monoclonal antibody in combination with BeiGene's tislelizumab, an anti-PD-1 monoclonal antibody in the Phase I clinical study  (NCT05431270) for the treatment of multiple advanced solid tumors.

• Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR Positive, HER2 Low or Negative Metastatic Breast Cancer

  12/8/2022

  Initial results from the TROPION-PanTumor01 phase 1 trial of datopotamab deruxtecan showed encouraging and durable efficacy in patients with heavily pretreated hormone receptor positive, HER2 low or HER2 negative unresectable or metastatic breast cancer.

• Camizestrant Significantly Delayed Disease Progression in Advanced ER-Positive Breast Cancer, Adding at Least 3.5 Months Benefit Versus FASLODEX® (fulvestrant)

  12/8/2022

  Detailed results from the SERENA-2 Phase II trial showed AstraZeneca’s next-generation oral selective estrogen receptor degrader (ngSERD) camizestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) at both 75mg and 150mg dose levels versus FASLODEX® (fulvestrant) 500mg in post-menopausal patients with estrogen receptor (ER)-positive locally advanced or metastatic breast cancer, previously treated with endocrine therapy.

• Dantari Debuts with $47 Million Series A to Advance Best-in-Class Targeted Medicines for Solid Tumors

  12/8/2022

  Dantari, Inc., a clinical-stage biotechnology company developing best-in-class targeted therapeutics for the treatment of cancers and other diseases, announced its emergence from stealth mode with $47 million Series A financing.

• Aarvik Therapeutics Announces a Global Novel Payload Agreement with NJ Bio, Inc.

  12/7/2022

  Aarvik Therapeutics announces a global license and assignment Agreement with NJ Bio, Inc. to secure a class of novel proprietary payloads with a wide range of potencies.

• ENHERTU® (fam-trastuzumab deruxtecan-nxki) Achieved Statistically Significant Overall Survival, Reducing the Risk of Death by 36% Vs. Trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Breast cancer in DESTINY-Breast03

  12/7/2022

  Updated results from the DESTINY-Breast03 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane.

• CytomX Therapeutics to Present Phase 2 Data for Praluzatamab Ravtansine (CX-2009) in Patients with Advanced Breast Cancer at the San Antonio Breast Cancer Symposium

  12/7/2022

  CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Phase 2 data for CX-2009, a conditionally activated antibody drug conjugate (ADC) targeting CD166, will be presented at the San Antonio Breast Cancer Symposium on December 8th.

• New Data for Trodelvy Demonstrate Clinical Efficacy Across Trop-2 Expression Levels in HR+/HER2- Metastatic Breast Cancer

  12/6/2022

  Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from a post-hoc analysis from the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy; SG) versus comparator chemotherapy (physicians’ choice of chemotherapy, TPC) in patients with HR+/HER2- metastatic breast cancer who progressed on endocrine-based therapies and at least two chemotherapies.

• Dragonfly Therapeutics Initiates Phase 2 Study of HER2 Targeting TriNKET® DF1001 in Patients with Advanced Solid Tumors

  12/6/2022

  Dragonfly Therapeutics, Inc. ("Dragonfly"), a biotechnology company developing novel therapies that harness the immune system to treat a broad range of diseases, today announced that the first patients have been dosed in the Phase 2 study of its HER2 targeting TriNKET® DF1001.

• Sorrento Therapeutics has Received FDA Clearance to Initiate Clinical Trials with a Next Generation mRNA (STI-1557) Vaccine Against Omicron SARS-CoV-2 Virus

  12/6/2022

  Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") has received clearance from the US FDA to initiate clinical trials with STI-1557, its next generation mRNA vaccine against SARS-CoV-2 Omicron variants.

• Defence Positioned to Begin Its Anti-Cancer AccuTOX(TM) Phase I Trial with Successful Completion of GLP Studies

  12/6/2022

  Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the successful completion of all GLP studies related to its anti-cancer AccuTOXTM molecule.

• Sorrento Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented at Asian Congress of the European Society for Medical Oncology (ESMO)

  12/5/2022

  Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) is pleased to announce the results of a Phase II NK/T-cell lymphoma study of IMC-001, a PD-L1 monoclonal antibody licensed to ImmuneOncia Therapeutics, LLC (“ImmuneOncia”) (Seongnam, South Korea). ImmuneOncia is a biotechnology company specializing in immuno-oncology drug development, jointly established by Yuhan Corporation of Korea and Sorrento.

• ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer’s Disease

  12/2/2022

  Anavex Life Sciences Corp. today announced positive topline results from its Phase 2b/3 ANAVEX®2-73-AD-004 clinical trial of oral ANAVEX®2-73 (blarcamesine) for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease.